{"title":"Avanir Licenses North American Rights to OptiNose’s NDA-Ready Drug-Device Combination for Migraine","authors":"Heather Cartwright","doi":"10.3833/PDR.V2013I7.1966","DOIUrl":null,"url":null,"abstract":"Avanir Pharmaceuticals has licensed North American rights to OptiNose’s Breath Powered™ intranasal delivery system containing low-dose sumatriptan powder for the treatment of acute migraine. The two companies will collaborate to complete the remaining activities needed to support regulatory submission of the drug-device combination, now known as AVP-825, with NDA filing expected by early 2014. If approved, AVP-825 will diversify Avanir’s CNS product portfolio beyond Nuedexta® (dextromethorphan plus quinidine sulphate), which is indicated for the treatment of pseudobulbar affect.","PeriodicalId":19951,"journal":{"name":"Pharmadeals Review","volume":"19 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2013-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmadeals Review","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3833/PDR.V2013I7.1966","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Avanir Pharmaceuticals has licensed North American rights to OptiNose’s Breath Powered™ intranasal delivery system containing low-dose sumatriptan powder for the treatment of acute migraine. The two companies will collaborate to complete the remaining activities needed to support regulatory submission of the drug-device combination, now known as AVP-825, with NDA filing expected by early 2014. If approved, AVP-825 will diversify Avanir’s CNS product portfolio beyond Nuedexta® (dextromethorphan plus quinidine sulphate), which is indicated for the treatment of pseudobulbar affect.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
